In this work, we present a continuation of the evaluation of matrilysins (MMP-7 and MMP-26) and stromelysins (MMP-3 and MMP-10) as novel tumor markers for women’s diseases [12,15,18]—this time, as screening biomarkers of EC. This evidence concerns the gene MMP26 and neoplasm.